# Phase 2 dementia trials recruiting: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 2 for dementia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 dementia trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/dementia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 9, 2026 | NCT07868718 | Peer Support for Family Caregivers of Older Adults Living With Dementia | Ohio State University | Phase 2 | Not yet recruiting | Caregiver Burden, Caregiver Burnout, Caregiver Anxiety, Alzheimer Disease Dementia | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868718) |
| September 22, 2026 | NCT07832383 | Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor | Neurocrine Biosciences | Phase 2 | Not yet recruiting | Alzheimer's Disease | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832383) |
| August 3, 2026 | NCT07741071 | N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease | Haukeland University Hospital | Phase 2 | Recruiting | Alzheimer Disease (AD) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741071) |
| December 12, 2025 | NCT07279740 | Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia | Sunnybrook Health Sciences Centre | Phase 2 | Recruiting | Alzheimer s Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease, Apathy, Apathy in Dementia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279740) |
| September 4, 2025 | NCT07154485 | Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Dementia Frontotemporal | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154485) |
| August 11, 2025 | NCT07115251 | Plans4Care: Personalized Dementia Care on Demand | Plans4Care Inc | Phase 2 | Not yet recruiting | Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115251) |
| August 6, 2025 | NCT07105709 | Open-label Extension Study in Participants With Early Alzheimer's Disease | GlaxoSmithKline | Phase 2 | Recruiting | Alzheimer's Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105709) |
| June 10, 2025 | NCT07012993 | Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012993) |
| May 4, 2025 | NCT06957418 | Alzheimer's Tau Platform: Master Protocol | Sponsor not shown (see the record) | Phase 2 | Recruiting | Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957418) |
| March 20, 2025 | NCT06887192 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | MapLight Therapeutics | Phase 2 | Recruiting | Psychosis Associated With Alzheimer's Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06887192) |
| February 12, 2025 | NCT06823752 | A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. | Woolcock Institute of Medical Research | Phase 2 | Recruiting | Insomnia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06823752) |
| January 17, 2025 | NCT06781333 | Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alzheimer Disease, Agitation in Dementia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06781333) |
| September 19, 2024 | NCT06604520 | Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia | Johns Hopkins University | Phase 2 | Recruiting | Fronto-temporal Dementia, Fronto-temporal Lobar Dementia, Frontotemporal Degeneration, Frontotemporal Dementia (FTD)... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06604520) |
| September 19, 2024 | NCT06588946 | Β-OHB Supplementation and Brain Health in Older Adults | McMaster University | Phase 2 | Not yet recruiting | Subjective Cognitive Decline | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06588946) |
| July 8, 2024 | NCT06489548 | Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease | Brigham and Women's Hospital | Phase 2 | Recruiting | Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06489548) |
| April 15, 2024 | NCT06364228 | Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia | University of Nebraska | Phase 2 | Recruiting | Stress | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06364228) |
| January 5, 2024 | NCT06191198 | Communication Bridge 3 Study | University of Chicago | Phase 2 | Recruiting | Primary Progressive Aphasia | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191198) |
| October 10, 2023 | NCT06072963 | COMMETS- Combination MCI Metabolic Syndrome | Rutgers, The State University of New Jersey | Phase 2 | Recruiting | Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06072963) |
| May 15, 2023 | NCT05858996 | Testing the Pain Clinical Practice Guideline | University of Maryland, Baltimore | Phase 2 | Recruiting | Pain, Dementia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05858996) |
| October 17, 2022 | NCT05582161 | Efficacy Biomarkers of DAOIB for Dementia | Chang Gung Memorial Hospital | Phase 2 | Recruiting | Dementia | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05582161) |
| January 6, 2022 | NCT05181189 | NMDA Enhancement Combined With Omega-3 for Early Dementia | Chang Gung Memorial Hospital | Phase 2 | Not yet recruiting | Omega 3 Fatty Acids, Dementia | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05181189) |
| October 23, 2020 | NCT04601038 | Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) | Johns Hopkins University | Phase 2 | Recruiting | Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04601038) |
| June 17, 2020 | NCT04436081 | Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease | Eastern Virginia Medical School | Phase 2 | Recruiting | Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04436081) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Chang Gung Memorial Hospital | 2 |
| Johns Hopkins University | 2 |
| University of Maryland, Baltimore | 1 |
| McMaster University | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Brigham and Women's Hospital | 1 |
| MapLight Therapeutics | 1 |
| Plans4Care Inc | 1 |
| University of Chicago | 1 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| Woolcock Institute of Medical Research | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Haukeland University Hospital | 1 |
| University of Nebraska | 1 |
| Eastern Virginia Medical School | 1 |
| Ohio State University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| Canada | 4 |
| Taiwan | 3 |
| Argentina | 2 |
| South Korea | 2 |
| Australia | 2 |
| Norway | 2 |
| Israel | 1 |
| Bulgaria | 1 |
| Chile | 1 |
| Czechia | 1 |
| France | 1 |
| Hungary | 1 |
| Italy | 1 |
| Poland | 1 |
| Portugal | 1 |
| Romania | 1 |
| Serbia | 1 |
| Slovakia | 1 |
| Finland | 1 |
| Spain | 1 |
| Sweden | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B direct mail advertising companies in the United States](https://specstream.ai/data/businesses/b2b-direct-mail-advertising-companies/united-states)
- [B2B advertising and marketing companies in the United States](https://specstream.ai/data/businesses/b2b-advertising-and-marketing-companies/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
